Awesome interview w/ @rheum_cat @JYazdanyMD @jeffsparks video link https://t.co/dVLayNchHT

• COVID in Rheumatologic Disease Patients: Drs. Sparks, Liew, Yazdany and Dao - Y…

Please don’t miss MISC (pronounced Miss C)=multisystem inflammatory syndrome. Pediatric syndrome post #SARSCoV2 infection. May go w macrophage activation syndrome (MAS) w distinct proteomics signature. Potentially v poor outcomes. Need to dx and treat #ACR21 abst0961 @RheumNow https://t.co/uaBbUdg3lt

Dr. Petri on COVID19 infection vs vaccination on SLE activity: 💠Infection = NO increase SLE activity 💠Infection =⬇️ cutaneous activity 💠Infection = ⬆️anti-cardiolipin IgG/M 💠Vaccination: no increase in activity NOR aCL IgG/M https://t.co/fWbotSLS3o #ACR21 Abst#0858 @RheumNow

• Effect of COVID Infection and COVID Vaccination on SLE Activity, Including Anti…

Abstr 0983 mRNA SARS-CoV-2 Vaccine in RA Patients Rubbert-Roth and colleagues found: - RA patients developed anti-S1 antibodies slower and lower compared to controls - Reduced titers among Abatacept & JAKi users #ACR21 @RheumNow https://t.co/sXW8d53O8m

#ACR21 #Abstr0866 Data from #COVID19 GRA Registry showed predictors of poor COVID outcome in 1922 #lupus pts: Older age Male Areas outside Europe, 🇺🇸🇨🇦 Infection <June 2020 Any Corticosteroid dose Not on therapy On Rituximab Comorbidities ⬆️disease activity @RheumNow #ACRBest https://t.co/u0GF3aDsFA

#ACR21 #Abstr0858 Petri reported effect of #COVID and vaccination in #lupus cohort 💠No increase in activity post-infection 💠⬇️cutaneous activity 💠⬆️ aCL IgG and IgM post-infection, 💠No increase in SLE activity or aCL abs post-vaccination @RheumNow https://t.co/iAaIfzf33c https://t.co/hA6sk6icrs

• Effect of COVID Infection and COVID Vaccination on SLE Activity, Including Anti…

Andy 0963 #ACR21 @RheumNow covid19 vaccine immunogenicity in rheum pts overall good at 71%, fairly dependent on Rx choice: rituximab 38% after 1g & only 7 % after 1gx2; abatacept IV 45%. Rest biologics >80%, ⬇️MTX &MMF. Low dose prednisone w/out biologics did not affect Ab+ rates https://t.co/TkCC1sgMHG

Infx oral session 0964 Bitoun, et al. RTX lowers neutralizing Ab response compared to healthy controls, after COVID vaccination -- more supportive data https://t.co/6jvWHSjIgr #ACR21

• Rituximab Treatment Dramatically Reduces Neutralizing Humoral Response to mRNA …

Outcomes of COVID-19 in Patients with Rheumatoid Arthritis. Dr. Akhil Sood ( @AkhilSoodMD) shares the studies presented #ACR21. https://t.co/yrs8N8XSiS https://t.co/EKHuTS5aDr

• https://bit.ly/2YmsXym

Results from @rheum_covid on #COVID19 outcomes in patients with #vasculitis #Abs0952 #ACR21 👉🏼~1000 pts 👉🏼Severe outcomes esp in #GCA and #AAV 👉🏼Older age, comorbidities, disease activity, high-dose steroids assoc with worse outcomes @RheumNow https://t.co/e2UlgDpyjw https://t.co/skoTKVYbEL

• Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and…

‘Cool’ explanation for #COVID toes. Type I IFN response can drive perniosis. Great session of cases from Len Calabrese & Jack Cush @RheumNow #ACR21 7S001 usual suspects https://t.co/v8IX2xxOZ7

@SattuiSEMD presents @rheum_covid data on COVID-19 outcomes in vasculitis/PMR. High rates of severe outcomes, particularly for AAV and GCA (mortality >20% for both). Multiple factors associated with outcomes (see below). Abstr#952 #ACR21 @RheumNow #ACRBest https://t.co/0lw1QhuJct

So important for our systemic vasculitis & PMR pts, @rheum_covid data highlighting the outsized COVID-19 risks they face. Thanks @SattuiSEMD @RichardPAConway @EBRheum in particular for driving forward this badly needed work! #ACR21 ABST0952 @RheumNow https://t.co/L7XS9OblxI https://t.co/LYxR1WUlhM

• David Liew on Twitter: &quot;Looking forward to hearing it presented by @Sattui…